Abstract

Patients with diabetes mellitus, especially the insulin-dependent variety, have increased circulating levels of growth hormone. On the basis of currently available information, the potential advantages of inhibition of growth hormone secretion as an adjunct in the treatment of diabetes mellitus include improved metabolic control (less hyperglycaemia, greater stability), resulting from diminution of the insulin-antagonistic actions of this hormone, and reduced micro- and possibly macro-angiopathy, resulting not only from improved metabolic control but also from decreased direct effects of growth hormone on blood vessels.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.